|
Nov 6
|
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
|
|
Nov 2
|
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
|
|
Jul 19
|
Acumen Announces Pricing of Upsized $130 Million Public Offering
|
|
Jul 18
|
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
|
|
Jul 17
|
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
Jul 17
|
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
|
|
Jul 16
|
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
|
|
Jul 16
|
Acumen's Alzheimer's drug passes initial safety test
|